Shares of Atossa Therapeutics (ATOS) have done what shares of most companies in the hunt for coronavirus solutions have done in 2020 – appreciate. Since the turn of the year, there has been 171% of upside for the Seattle-based biotech firm.Despite the impressive gains, the micro-cap still has a market cap of only $39 million. Going by his revised outlook for Atossa, Maxim’s 5-star analyst Jason McCarthy believes the stock remains seriously undervalued.McCarthy recently doubled his price target from $4 to $8. The implication for investors? Upside of a very hefty 119%. There’s no change to McCarthy’s rating, which remains …read more
Source:: Yahoo Finance
